‹ Screener

INOVIO PHARMACEUTICALS, INC.

INO · Pharmaceutical Preparations · 82.3M shares · -28%/yr ↓ buyback · EDGAR filings ↗

Grade

D40

Clinical/early-stage biotech — deep burn, revenue collapse

Strengths

Risks

Notable findings

Quarterly revenue

2025-06-30 · $02025-09-30 · $02025-12-31 · $02026-03-31 · $0

Last 4 quarters · from SEC filings.

Key metrics

Operating margin
-132871.3%
Net margin
-130000.0%
Return on equity
-352.5%
Return on assets
-114.3%
Revenue growth (QoQ)
-70.0%
Current ratio
1.4×
Free cash flow
-$89M
Tangible book value
$24M
Cash & investments
$58M
Cash runway
3q
Stock comp / revenue
5747.8%

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-05-20Sumner Michael JohnOption exercise9.4K
2026-05-20Sumner Michael JohnTax withheld2.7K$1.23
2026-05-20Shea Jacqueline ElizabethOption exercise28K
2026-05-20Shea Jacqueline ElizabethTax withheld12K$1.23
2026-05-20Humeau LaurentOption exercise6.0K
2026-05-20Humeau LaurentTax withheld2.2K$1.23
2026-05-20KIES PETEROption exercise8.7K
2026-05-20KIES PETERTax withheld4.7K$1.23
2026-05-15Sumner Michael JohnOption exercise2.4K
2026-05-15Sumner Michael JohnTax withheld680$1.30
2026-05-15Shea Jacqueline ElizabethOption exercise18K
2026-05-15Shea Jacqueline ElizabethTax withheld7.7K$1.30
2026-05-15Humeau LaurentOption exercise4.8K
2026-05-15Humeau LaurentTax withheld1.7K$1.30
2026-05-15KIES PETEROption exercise4.8K
2026-05-15KIES PETERTax withheld2.6K$1.30
2026-03-31Sumner Michael JohnOption exercise4.3K
2026-03-31Sumner Michael JohnTax withheld1.2K$1.74
2026-02-26Sumner Michael JohnOption exercise5.0K
2026-02-26Sumner Michael JohnOption exercise12K
2026-02-26Sumner Michael JohnTax withheld3.9K$1.79
2026-02-26Shea Jacqueline ElizabethOption exercise19K
2026-02-26Shea Jacqueline ElizabethTax withheld8.1K$1.79
2026-02-26Shea Jacqueline ElizabethOption exercise28K
2026-02-26Shea Jacqueline ElizabethTax withheld14K$1.79
2026-02-26Humeau LaurentOption exercise5.0K
2026-02-26Humeau LaurentTax withheld2.1K$1.79
2026-02-26Humeau LaurentOption exercise7.4K
2026-02-26Humeau LaurentTax withheld3.0K$1.79
2026-02-26Weiner David B.Option exercise972
2026-02-26KIES PETEROption exercise5.0K
2026-02-26KIES PETERTax withheld3.0K$1.79
2026-02-26KIES PETEROption exercise11K
2026-02-26KIES PETERTax withheld6.3K$1.79
2025-06-30Sumner Michael JohnOption exercise2.9K
2025-05-21Zoth Lota S.Option exercise2.2K
2025-05-21Miller Ann CalbyOption exercise2.2K
2025-05-21Shepard JayOption exercise2.2K
2025-05-21BENITO SIMON XOption exercise2.2K
2025-05-21YARNO WENDY LOption exercise2.2K
2025-05-21DANSEY ROGER DOption exercise2.2K
2025-05-21Weiner David B.Option exercise2.2K
2025-05-15Sumner Michael JohnOption exercise2.4K
2025-05-15Sumner Michael JohnTax withheld680$1.95
2025-05-15Shea Jacqueline ElizabethOption exercise18K
2025-05-15Shea Jacqueline ElizabethTax withheld7.7K$1.95
2025-05-15KIES PETEROption exercise4.8K
2025-05-15KIES PETERTax withheld2.6K$1.95
2025-05-15Humeau LaurentOption exercise4.8K
2025-05-15Humeau LaurentTax withheld1.7K$1.95
2025-05-10Shea Jacqueline ElizabethOption exercise5.5K
2025-05-10Shea Jacqueline ElizabethTax withheld2.4K$1.80
2025-02-26Humeau LaurentOption exercise3.9K
2025-02-26Humeau LaurentTax withheld1.6K$1.98
2025-02-26Humeau LaurentOption exercise5.0K
2025-02-26Humeau LaurentTax withheld2.1K$1.98
2025-02-26Sumner Michael JohnOption exercise5.0K
2025-02-26Shea Jacqueline ElizabethOption exercise5.9K
2025-02-26Shea Jacqueline ElizabethTax withheld2.5K$1.98
2025-02-26Shea Jacqueline ElizabethOption exercise19K
2025-02-26Shea Jacqueline ElizabethTax withheld9.1K$1.98
2025-02-26KIES PETEROption exercise4.0K
2025-02-26KIES PETERTax withheld2.4K$1.98
2025-02-26KIES PETEROption exercise5.0K
2025-02-26KIES PETERTax withheld3.0K$1.98
2025-02-26Weiner David B.Option exercise972
2025-02-26Weiner David B.Option exercise972

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT02464670 ↗Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Ebola Vaccine
PHASE1Completed2018-05-24

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

DateItems
2026-05-205.03Shareholder voteExhibitsfiling ↗
2026-05-13ResultsExhibitsfiling ↗
2026-04-06Material agreementOtherExhibitsfiling ↗
2026-04-02Otherfiling ↗
2026-03-12ResultsExhibitsfiling ↗
2026-01-27Material agreement3.03Exhibitsfiling ↗
2025-12-29Reg FDOtherExhibitsfiling ↗
2025-11-12Material agreementOtherExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-05-202026-05-190001193125-26-232524 ↗
10-Q2026-05-132026-03-310001055726-26-000018 ↗
8-K2026-05-132026-05-130001055726-26-000019 ↗
8-K2026-04-062026-04-020001193125-26-142885 ↗
8-K2026-04-022026-04-010001193125-26-138870 ↗
10-K2026-03-122025-12-310001055726-26-000008 ↗
8-K2026-03-122026-03-120001055726-26-000009 ↗
8-K2026-01-272026-01-270001193125-26-024431 ↗
8-K2025-12-292025-12-290001193125-25-332322 ↗
8-K2025-11-122025-11-110001193125-25-275721 ↗
10-Q2025-11-102025-09-300001055726-25-000063 ↗
8-K2025-11-102025-11-100001055726-25-000064 ↗